Researchers are studying different adjuvants, antigens, and routes of immunization to ascertain the most appropriate system of immune protection; however, most of the research only recently moved from animal to human trials.
The standardization of parameters such as the lethal dose (LD50), volume of the cultures to be inoculated, most appropriate inoculation location, and intervals between immunizations were performed according to Ribeiro et al. [ 15].
Detailed outbreak investigations and collection of additional data (compilation of line-lists) are recommended to describe the epidemiology and the age distribution of the epidemic, to guide rapid and effective reactive immunization campaigns and to target the most appropriate age groups.
While the public health approach to wild-type measles infection in terms of contact tracing, isolation, and post exposure immunization or immune globulin is well described [ 1], the most appropriate course of action in cases of vaccine-associated measles in immunocompromised individuals is not clear.
It would useful to determine which staff makes the most effective immunization champion and what sort of training is most appropriate.
Although, all rabbits responded well to the repetitive immunizations, however in order to select the most appropriate animal for scarifying and collecting the total sera, the affinity of these antisera from all animals were checked by competitive ELISA as described above.
Consequently, a criterion for choosing appropriate immunization risk measures is to take those developed from the most reasonable sets of shocks and the associated subset of worst shocks and then select those that work best empirically.
Two or three immunizations with a dose of 30 µg formulated with AS02A appeared the most appropriate choice for such studies.
Considering that the two adjuvant formulations were well tolerated and safe, that the highest antibody and IFN-γ responses were induced with AS02A formulations, that doses of 30 µg and 100 µg of peptide induced similar responses, two or three immunizations with a dose of 30 µg of PfCS102 formulated preferentially with AS02A seem the most appropriate choice for future clinical challenge studies.
"That is the most appropriate vehicle".
